So, you have no science. What you have there is more politics. Find the science that’s shows HCQ as an early treatment (5 days) doesn’t work when given with zinc, antibiotics, vitamin D. Non hospitalized setting. Show me the data. I’ve posted article after article to you nitwits and you come back with politics.
No science?? What the hell is coming out of Yale for example...?? See if the following science does anything to enlighten you........and there is a helluva lot more out there.... This a full paper...with author affiliations . I pulled out key charts and text for you....
Original Investigation
November 9, 2020
Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19A Randomized Clinical Trial
Wesley H. Self, MD, MPH1; Matthew W. Semler, MD2; Lindsay M. Leither, DO3,4; et al Jonathan D. Casey, MD, MSc2; Derek C. Angus, MD, MPH5; Roy G. Brower, MD6; Steven Y. Chang, MD, PhD7; Sean P. Collins, MD1; John C. Eppensteiner, MD8; Michael R. Filbin, MD9; D. Clark Files, MD10; Kevin W. Gibbs, MD10; Adit A. Ginde, MD, MPH11; Michelle N. Gong, MD, MS12; Frank E. Harrell Jr, PhD13; Douglas L. Hayden, PhD14; Catherine L. Hough, MD, MSc15; Nicholas J. Johnson, MD16; Akram Khan, MD15; Christopher J. Lindsell, PhD13; Michael A. Matthay, MD17; Marc Moss, MD18; Pauline K. Park, MD19; Todd W. Rice, MD2; Bryce R. H. Robinson, MD, MS20; David A. Schoenfeld, PhD14; Nathan I. Shapiro, MD, MPH21; Jay S. Steingrub, MD22; Christine A. Ulysse, MS14; Alexandra Weissman, MD, MPH23; Donald M. Yealy, MD23; B. Taylor Thompson, MD24; Samuel M. Brown, MD, MS3,4; for the National Heart, Lung, and Blood Institute PETAL Clinical Trials Network
Author Affiliations Article Information
JAMA. 2020;324(21):2165-2176. doi:10.1001/jama.2020.22240
COVID-19 Resource Center
visual abstract icon
Editorial
Misguided Use of Hydroxychloroquine for COVID-19
Michael S. Saag, MD
Original Investigation
Treatment With Hydroxychloroquine or Azithromycin and In-Hospital Mortality in Patients With COVID-19
Eli S. Rosenberg, PhD; Elizabeth M. Dufort, MD; Tomoko Udo, PhD; Larissa A. Wilberschied, MS; Jessica Kumar, DO; James Tesoriero, PhD; Patti Weinberg, PA; James Kirkwood, MPH; Alison Muse, MPH; Jack DeHovitz, MD; Debra S. Blog, MD; Brad Hutton, MPH; David R. Holtgrave, PhD; Howard A. Zucker, MD
Original Investigation
Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers
Benjamin S. Abella, MD, MPhil; Eliana L. Jolkovsky, BA; Barbara T. Biney, MPH; Julie E. Uspal, MD; Matthew C. Hyman, MD, PhD; Ian Frank, MD; Scott E. Hensley, PhD; Saar Gill, MD, PhD; Dan T. Vogl, MD, MSCE; Ivan Maillard, MD, PhD; Daria V. Babushok, MD; Alexander C. Huang, MD, PhD; Sunita D. Nasta, MD; Jennifer C. Walsh; E. Paul Wiletyo, PhD; Phyllis A. Gimotty, PhD; Michael C. Milone, MD, PhD; Ravi K. Amaravadi, MD; and the Prevention and Treatment of COVID-19 With Hydroxychloroquine (PATCH) Investigators
Audio Clinical Review (13:03)
Why Are We Still Talking About Hydroxychloroquine as a Treatment for COVID-19?
Key PointsQuestion Does treatment with hydroxychloroquine improve clinical outcomes of adults hospitalized with coronavirus disease 2019 (COVID-19)?
Findings In this randomized clinical trial that included 479 hospitalized adults with respiratory symptoms from COVID-19, the distribution of the day 14 clinical status score (measured using a 7-category ordinal scale) was not significantly different for patients randomized to receive hydroxychloroquine compared with placebo (adjusted odds ratio, 1.02).
Meaning These findings do not support the use of hydroxychloroquine for treatment of COVID-19 among hospitalized adults.
 |
